logo
  

Identiv Appoints Justin Scarpulla As New CFO - Quick Facts

Identiv, Inc. (INVE), a global leader in digital security and identification in the Internet of Things (IoT), announced Thursday that Justin Scarpulla will be appointed as Chief Financial Officer, effective December 6, 2021.

Interim CFO Ed Kirnbauer will remain at Identiv as Global Corporate Controller and a key leader within Scarpulla's financial team.

Scarpulla brings more than 25 years of financial leadership experience to Identiv. He joins Identiv from SpaceX, which designs, manufactures, and launches advanced rockets and spacecraft, as well as operating the Starlink internet constellation, deploying thousands of advanced communications satellites. While at SpaceX, he managed business leadership engagement across the company, reporting to SpaceX CFO Bret Johnsen.

Prior to SpaceX, Scarpulla was Vice President of Finance and Accounting at Incipio and Vice President and Corporate Controller at Vizio. He also served as Chief Accounting Officer and Controller at MaxLinear, an NYSE-listed semiconductor company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Discount retailer Target Corp. is recalling about 23,400 units of Cloud Island 4-Piece Plush Toy Sets citing choking risk, the U.S. Consumer Product Safety Commission said. The recall involves toy vehicle sets, which are a soft, knitted construction and include a blue car, a yellow bus, a red tractor, and a green truck each with a rattle inside. Retailers Dollar General Corp. (DG) and Big Lots, Inc. (BIG) reported Thursday results for the third quarter, with profit at Dollar General increasing from last year, while Big Lots reported a sharply wider loss than last year. The bottom line at both the retailers missed analysts' estimates. The U.S. Food and Drug Administration said it has granted approval for Ferring Pharmaceuticals Inc.'s fecal microbiota product Rebyota. The approval is for the prevention of recurrence of Clostridioides difficile infection or CDI in individuals 18 years of age and older. Rebyota will be used after an individual has completed antibiotic treatment for recurrent CDI.
RELATED NEWS
Follow RTT